The SPERA trial is designed to 1. provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited cytotoxic chemotherapy regimens for metastatic disease and 2. to evaluate the safety of oral satraplatin in this patient population.
\*\*\*\*\*UPDATE\*\*\*\*\* On October 30th, 2007 GPC Biotech announced topline overall survival results for the Phase III trial in hormone refractory prostate cancer-Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial. The trial evaluated satraplatin plus prednisone versus placebo plus prednisone as a second-line treatment in 950 patients with hormone-refractory prostate cancer (HRPC). The companies reported that the trial did not achieve the endpoint of overall survival (p=0.80, stratified log rank analysis). The median was 61.3 weeks for the satraplatin arm compared to 61.4 weeks for the control group and the hazard ratio was 0.97 (95% CI: 0.83, 1.13). The companies are currently conducting pre-specified subset analyses. Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
344
The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited prior cytotoxic chemotherapy regimens for metastatic disease.
Time frame: Patient evaluation by MD at baseline to determine eligibility.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Carraway Cancer Clinic
Birmingham, Alabama, United States
Birmingham Hematology and Oncology
Birmingham, Alabama, United States
Urology Centers of Alabama
Homewood, Alabama, United States
Providence Alaska Medical Center
Anchorage, Alaska, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
Clopton Clinic
Jonesboro, Arkansas, United States
Pacific Cancer Medical Center, Inc
Anaheim, California, United States
East Valley Hematology Oncology Medical Group
Burbank, California, United States
Pacific Shores Medical Group
Long Beach, California, United States
North Valley Hematology/Oncology Medical Group
Mission Hills, California, United States
...and 111 more locations